Tags |
|
|
Links |
|
|
Top Adding - The New Fad In The Debt-Laden Era!
Okay, it’s not all bad news and borrowing money is not always a bad thing if you can afford to do so. Whereas we
According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
would all like to be in a position to pay cash for a car or a house, in reality this is not an option.
However,
However,
; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.
Examples of combination products may in
Examples of combination products may in
when the economy is buoyant, we’re all susceptible to spending! This is especially the case when house prices ri
lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.
se! With our new found wealth in our properties we all merrily borrow against them and before we know it, we’re
here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
truggling to pay back our mortgages and loans…
Many people have found themselves in this position, some are able
Many people have found themselves in this position, some are able
d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.
Combination pro
Combination pro
to ‘trade’ out of it and obtain re-mortgages or consolidation loans whereas for others the strain becomes too muc
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
h and they find themselves looking for a non-borrowing option as their income cannot match their monthly outgoing
easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
.
The product set here consists generally of two types of package outside of complete bankruptcy; the debt-manag
The product set here consists generally of two types of package outside of complete bankruptcy; the debt-manag
nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
ement plan and the IVA or Individual Voluntary Arrangement. In essence the difference is that one is a legally b
and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
nding agreement whereas the other is not. Of late, IVA’s have become very ‘fashionable’ for both customers and p
ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
oviders alike, since they are the legally binding product and are more likely to provide continued revenue for th
ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.
Following aspects would a
Following aspects would a
e provider. However, as more providers have cropped up, as a direct result of the ever-increasing number of peop
dd to the challenges in developing combination products:
Which markets to tap where the combination products can do fairly well?
Which combination prod
Which markets to tap where the combination products can do fairly well?
Which combination prod
e going into serious debt, margins for the providers have also been eroded. Not only by competition amongst the p
cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin
roviders for customers but also by pressure from regulatory bodies that believe these companies are making too mu
tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
What would be the developing cost?
How to tackle the risks encountered during combination product developmen
h money from people who are in serious debt.
With too much choice, comes confusion and the customer is left bewi
With too much choice, comes confusion and the customer is left bewi
t?
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
dered by the different companies pitching for their business. In many cases however, a customer may not even kno
ping new procedures for reviewing their safety, efficacy and quality.
Professional from academic institutions, pharmaceutical industries, health care indust
Professional from academic institutions, pharmaceutical industries, health care indust
w that an IVA is a valid option for them to the extent that they are unaware of the product. As a result the cus
y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
omer responds to the IVA companies advertising which normally focuses on ‘wiping out or significantly reducing’ t
.
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
heir debt. There are advertising rules and regulations surrounding what can and can’t be said and even recently
elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.
Companies that provide selfless information through particip
Companies that provide selfless information through particip
wo UK companies have been cited for inappropriate advertising, forcing them to remove the advertising in question
tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.topadding.org.ua/article/99619/topadding-The-New-Fad-In-The-DebtLaden-Era.html">The New Fad In The Debt-Laden Era!</a>
BB link (for phorums):
[url=http://www.topadding.org.ua/article/99619/topadding-The-New-Fad-In-The-DebtLaden-Era.html]The New Fad In The Debt-Laden Era![/url]
Related Articles:
How the Big Boys do Relationship Marketing
A Much Easier Way To Make Your Own Web Site
Bookmark it:
|